PHE Study on Value of Novel Immuno-Oncology Treatments Featured in AJMC
A new study by Precision co-authors Andrew Delgado and Jinjoo Shim, along with scientific advisors John Romley and Katherine Batt, assesses the value to society of improved survival from novel immune-oncology treatments. With the data compiled, the study team concluded that there is evidence of substantial survival gains, and thus, social value.
Appearing in the latest American Journal of Managed Care (AJMC), the abstract and study can be found here.
Led by Caroline Huber, Associate Director of Policy and Economics, a surprising new study was recently published in The Journal of Infectious Diseases, estimating the overlooked social, economic and health impacts of the 2013-2016 West Africa Ebola crisis.